NCT03922555招募中1 期
Phase I Trial of ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 18
- 试验地点
- 4
- 主要终点
- Maximum tolerated dose
研究概览
简要总结
this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.
详细描述
This research study is a Phase I clinical trial, which tests the safety of an investigational drug and also tries to define the appropriate dose of the investigational drug to use for further studies. "Investigational" means that the drug is being studied.
The FDA (the U.S. Food and Drug Administration) has not approved ASTX727 as a treatment for any disease.
ASTX727 is made up of the 2 study drugs cedazuridine and decitabine. Cedazuridine is believed to work by slowing down how fast decitabine is broken down by the body. Decitabine is believed to work by blocking abnormal cells or cancer cells from growing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must be ≥18 years of age.
- •Participants must have histologically or cytologically confirmed glioma, with documented IDH1 and/or IDH2 gene-mutation.
- •Participants must have radiographic evidence of non-enhancing disease progression/recurrence per RANO criteria for low grade gliomas (LGG).
- •Patients who have received prior treatment with chemotherapy, radiation, or a combination of both are eligible. Also, patients who have not received any prior treatment for their glioma are also eligible.
- •Participants must be ≥12 weeks from completion of radiation.
- •Participants must have a baseline brain MRI scan within 28 days prior to Day 1 of treatment.
- •Participants must be on a stable or decreasing dose of glucocorticoids for 7 days prior to registration.
- •Participants must have archived primary tumor biopsies or surgical specimens for additional exploratory translational studies. At least 100-micron length of FFPE tissue or a tissue block should be available for enrollment and for shipment to the Sponsor, or a laboratory designated by the Principal Investigator. If less material is available, participants could still be eligible after discussion with the Principal Investigator who will assess and confirm that there is sufficient material for key evaluations.
- •Participants must be able to understand and willing to sign an informed consent. A legally authorized representative may consent on behalf of a participant who is otherwise unable to provide informed consent, if acceptable to and approved by the site and/or site's Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
- •Participants must have KPS ≥ to 70
- •Participants must have expected survival of ≥ 6 months.
- •Participants must have adequate bone marrow function as evidenced by:
- •Leukocytes ≥ 3,000/mcL
- •Absolute neutrophil count ≥1500/mcL;
- •Hemoglobin ≥10 g/dL
- •Platelets ≥100,000/mcL
- •Participants must have adequate hepatic function as evidenced by:
- •Serum total bilirubin ≤1.5 x upper limit of normal (ULN), unless considered due to Gilbert's disease
- •Aspartate aminotransferase (AST), Alanine Aminotransferase (ALT), and alkaline phosphatase (ALP) ≤3.0 x ULN.
- •Participants must have adequate renal function as evidenced by:
- •Serum creatinine ≤2.0 x ULN
- •OR Creatinine clearance >40 mL/min based on the Cockroft-Gault glomerular filtration rate (GFR) estimation: (140 - Age) × (weight in kg) × (0.85 if female)/72 × serum creatinine
- •Participants must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer. (Participants with residual Grade 1 toxicity due to prior chemotherapy are allowed).
- •Female participants with reproductive potential must have a negative serum pregnancy test within 14 days prior to the first study drug administration. Participants with reproductive potential are defined as sexually mature women who have not undergone a hysterectomy, bilateral oophorectomy or tubal occlusion or who have not been naturally postmenopausal (i.e., who have not menstruated at all) for at least 24 consecutive months (i.e., have had menses at any time in the preceding 24 consecutive months). Women with reproductive potential as well as fertile men and their partners who are female with reproductive potential must agree to abstain from sexual intercourse or to use 2 effective forms of contraception from the time of giving informed consent, during the study, and for 90 days (females and males) following the last dose of ASTX
- •Participants enrolling in the expansion cohort (Arm B) must meet all of the above criteria and must have surgically accessible tumors and be surgical candidates.
排除标准
- •Participants with enhancing disease on brain MRI.
- •Participants who received systemic anticancer therapy <28 days prior to registration. One exception: participants on lomustine/CCNU must wait at least 42 days from last date of drug administration to registration.
- •Participants who received an investigational agent <14 days prior to registration. In addition, the first dose of ASTX727 should not occur before a period ≥5 half-lives of the investigational agent has elapsed.
- •Participants with prior treatment with bevacizumab (Avastin) are excluded.
- •Participants who are pregnant or breast-feeding.
- •Participants with an active severe infection that requires anti-infective therapy or with an unexplained fever >38.5°C during screening visits or on their first day of study drug administration.
- •Participants with known additional malignancy that is progressing or requires active treatment within 2 years of start of study drug. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, in situ cervical cancer that has undergone potentially curative therapy, or surgically treated prostate cancer.
- •Participants with known hypersensitivity to any of the components of ASTX
- •Participants with a history of myocardial infarction within the 6 months prior to screening.
- •Participants with a known history of severe and/or uncontrolled ventricular arrhythmias.
- •Participants with QTc interval ≥450 msec or with other factors that significantly increase the risk of QT prolongation or arrhythmic events (e.g., family history of long QT interval syndrome).
- •Participants with known infection with human immunodeficiency virus (HIV) or active hepatitis B or C.
- •Participants with any other medical or psychological condition, deemed by the Investigator to be likely to interfere with a participant's ability to sign informed consent, cooperate, or participate in the study.
- •Participants with known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.
- •Participants with evidence of intracranial or intratumoral hemorrhage either by MRI or CT scan. Participants with resolving post-surgical changes, punctate/micro-hemorrhage, or hemosiderin are eligible.
- •Participants enrolling in the expansion cohort will be excluded is they are deemed by the treating physician or surgeon not to be suitable for surgery
研究组 & 干预措施
ASTX727 (Cedazuridine + Cytidine Antimetabolite Decitabine)
Experimental
-ASTX727 administered orally for 5 or 6 consecutive days every 28d cycle and will de-escalate to 4 consecutive days every 28 d cycle.
干预措施: ASTX727 (Drug)
Expansion Cohort
Experimental
- Oral ASTX727 will be administered daily for 4, 5 or 6 consecutive days
- Surgical resection will take place 12 days (+/- 1 day) after initiation of treatment
干预措施: ASTX727 (Drug)
结局指标
主要结局
Maximum tolerated dose
时间窗: 1 year
Participants will be enrolled at escalating doses using a standard 3+3 dose escalation design until the maximum administered dose is reached or until dose limiting toxicities result in the end of dose escalation. The maximum tolerated dose is the highest administered dose level at which participants experienced experienced 1 or fewer dose limiting toxicities.
次要结局
- Median Progression Free Survival(From the time of randomization until disease progression or death, up to five years)
- Overall Survival(From the time of randomization until death, up to five years)
- Response Rate(1 Year)
研究者
Isabel Arrillaga-Romany
Principal Investigator
Massachusetts General Hospital
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)MDSMyelodysplastic SyndromeNCT02103478Astex Pharmaceuticals, Inc.130
已完成
1 期
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast CancerTriple Negative Breast CancerHormone Receptor Positive TumorMetastatic Breast CancerNCT04134884Kathy Miller34
已完成
1 期
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid TumorsAdvanced MalignancyAdvanced Solid TumorsMetastasisNeoplasmNCT02743637SynDevRx, Inc.32
撤回
1 期
A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT06113289M.D. Anderson Cancer Center42
已完成
1 期
Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid CancersNeoplasmsNCT00969553Boehringer Ingelheim59